恩替卡韦治疗乙型肝炎肝硬化的疗效观察

目的观察恩替卡韦治疗乙型肝炎肝硬化的临床疗效。方法将88例乙型肝炎肝硬化患者随机分为治疗组和对照组,各44例。对照组给予常规保肝及对症治疗,治疗组在常规治疗基础上加恩替卡韦0.5 mg/d,疗程1年。观察两组患者肝功能、Child-Pugh评分、HBV DNA、肝纤维化指标（HA、LN、PⅢP、Ⅳ-C）的变化。结果治疗组总有效率为95.5%,对照组总有效率为63.6%,治疗组总有效率显著高于对照组（P〈0.01）。两组患者治疗前后肝纤维化指标（HA、LN、PⅢP、Ⅳ-C）、肝功能及Child-Pugh评分比较差异均有统计学意义（P〈0.05）,治疗组患者治疗12周后肝纤维化指标、肝功能、Child-Pugh评分及HBV DNA均较对照组显著改善（P〈0.05）。结论恩替卡韦治疗乙型肝炎肝硬化疗效显著,不良反应少,耐受性好,是一种有效、安全且理想的药物

Observation of effect on Entecavir in the treatment of hepatitis B cirrhosis

Objective To observe clinical effect of hepatitis B cirrhosis treated with Entecavir.Methods 88 patients with hepatitis B cirrhosis were divided into treatment group(44 patients) and control group(44 patients) randomly.The control group received conventional liver-protecting and symptomatic treatment only,while the treatment group received additional Entecavir(0.5 mg/d,one year course).The liver function,Child-Pugh grade,HBV DNA and liver fibrosis markers(HA,LN,PⅢP and Ⅳ-C) of two groups were observed.Results The total effective rate of treatment group(95.5%) was higher than control group(63.6%)(P < 0.01).After treatment,the liver fibrosis markers(HA,LN,PⅢP and Ⅳ-C),liver function and Child-Pugh grade in both groups were significantly improved(P < 0.05).There were significant differences of liver fibrosis markers(HA,LN,PⅢP and Ⅳ-C),liver function,Child-Pugh grade and HBV DNA between treatment group and control group after treatment(P < 0.05).Conclusion Entecavir has significant clinical effect,low adverse reaction and good tolerance in treating patients with hepatitis B cirrhosis.